N Yoshimura1, S Muraki, H Oka, K Nakamura, H Kawaguchi, S Tanaka, T Akune. 1. Department of Joint Disease Research, 22nd Century Medical and Research Center, Graduate School of Medicine, The University of Tokyo, 7-3-1 Hongo, Bunkyo-ku, Tokyo, 113-8655, Japan, YOSHIMURAN-ORT@h.u-tokyo.ac.jp.
Abstract
UNLABELLED: Assessment of serum 25-hydroxyvitamin D levels in association with the occurrence of musculoskeletal diseases using a population-based cohort study design revealed that serum 25-hydroxyvitamin D levels could predict the occurrence of osteoporosis at the femoral neck within 3 years, but not the occurrence of knee osteoarthritis or lumbar spondylosis. INTRODUCTION: The aim of this study is to clarify the association between serum 25-hydroxyvitamin D (25D) levels and occurrence of osteoporosis and osteoarthritis in the general population. METHODS: The Research on Osteoarthritis/Osteoporosis Against Disability study, a large-scale population-based cohort study, was performed during 2005-2007. Serum 25D levels were measured in 1,683 participants. Of these, 1,384 individuals (81.9%) completed a second follow-up survey 3 years later. Osteoporosis was defined according to World Health Organization criteria, in which osteoporosis is diagnosed by T-scores of bone mineral density (BMD) that are 2.5 standard deviations (SD) less than normal BMD. Knee osteoarthritis and lumbar spondylosis were defined as Kellgren-Lawrence grade ≥2, using paired X-ray films. Cumulative incidences were determined according to changes in measurements using World Health Organization criteria for osteoporosis or Kellgren-Lawrence grades for osteoarthritis between the baseline and second survey. RESULTS: The mean (SD) serum 25D level of the 1,384 participants in both surveys was 23.4 ng/mL (6.5). The annual cumulative incidences of osteoporosis at L2-4 and the femoral neck were 0.76 and 1.83%/year, respectively. The incidences of knee osteoarthritis and lumbar spondylosis were 3.3 and 11.4%/year, respectively. After adjusting for potential associated factors, logistic regression analyses revealed that the odds ratio for the occurrence of femoral neck osteoporosis significantly decreased as serum 25D levels increased (+1 SD; odds ratio 0.67; 95% confidence interval 0.49-0.92; p = 0.014). CONCLUSIONS: Higher serum 25D levels may prevent the occurrence of osteoporosis at the femoral neck, but not knee osteoarthritis, lumbar spondylosis, or osteoporosis at L2-4.
UNLABELLED: Assessment of serum 25-hydroxyvitamin D levels in association with the occurrence of musculoskeletal diseases using a population-based cohort study design revealed that serum 25-hydroxyvitamin D levels could predict the occurrence of osteoporosis at the femoral neck within 3 years, but not the occurrence of knee osteoarthritis or lumbar spondylosis. INTRODUCTION: The aim of this study is to clarify the association between serum 25-hydroxyvitamin D (25D) levels and occurrence of osteoporosis and osteoarthritis in the general population. METHODS: The Research on Osteoarthritis/Osteoporosis Against Disability study, a large-scale population-based cohort study, was performed during 2005-2007. Serum 25D levels were measured in 1,683 participants. Of these, 1,384 individuals (81.9%) completed a second follow-up survey 3 years later. Osteoporosis was defined according to World Health Organization criteria, in which osteoporosis is diagnosed by T-scores of bone mineral density (BMD) that are 2.5 standard deviations (SD) less than normal BMD. Knee osteoarthritis and lumbar spondylosis were defined as Kellgren-Lawrence grade ≥2, using paired X-ray films. Cumulative incidences were determined according to changes in measurements using World Health Organization criteria for osteoporosis or Kellgren-Lawrence grades for osteoarthritis between the baseline and second survey. RESULTS: The mean (SD) serum 25D level of the 1,384 participants in both surveys was 23.4 ng/mL (6.5). The annual cumulative incidences of osteoporosis at L2-4 and the femoral neck were 0.76 and 1.83%/year, respectively. The incidences of knee osteoarthritis and lumbar spondylosis were 3.3 and 11.4%/year, respectively. After adjusting for potential associated factors, logistic regression analyses revealed that the odds ratio for the occurrence of femoral neck osteoporosis significantly decreased as serum 25D levels increased (+1 SD; odds ratio 0.67; 95% confidence interval 0.49-0.92; p = 0.014). CONCLUSIONS: Higher serum 25D levels may prevent the occurrence of osteoporosis at the femoral neck, but not knee osteoarthritis, lumbar spondylosis, or osteoporosis at L2-4.
Authors: H Orimo; Y Hayashi; M Fukunaga; T Sone; S Fujiwara; M Shiraki; K Kushida; S Miyamoto; S Soen; J Nishimura; Y Oh-Hashi; T Hosoi; I Gorai; H Tanaka; T Igai; H Kishimoto Journal: J Bone Miner Metab Date: 2001 Impact factor: 2.626
Authors: S Muraki; T Akune; H Oka; Y Ishimoto; K Nagata; M Yoshida; F Tokimura; K Nakamura; H Kawaguchi; N Yoshimura Journal: Osteoarthritis Cartilage Date: 2012-04-04 Impact factor: 6.576
Authors: N Yoshimura; S Muraki; H Oka; A Mabuchi; H Kinoshita; M Yosihda; H Kawaguchi; K Nakamura; T Akune Journal: Osteoporos Int Date: 2008-11-07 Impact factor: 4.507
Authors: N Yoshimura; S Muraki; H Oka; M Morita; H Yamada; S Tanaka; H Kawaguchi; K Nakamura; T Akune Journal: Osteoporos Int Date: 2013-05-15 Impact factor: 4.507
Authors: Arjan P Bergink; André G Uitterlinden; Johannes P T M Van Leeuwen; Cok J Buurman; Albert Hofman; Jan A N Verhaar; Huibert A P Pols Journal: J Clin Rheumatol Date: 2009-08 Impact factor: 3.517
Authors: Heike A Bischoff-Ferrari; Douglas P Kiel; Bess Dawson-Hughes; John E Orav; Ruifeng Li; Donna Spiegelman; Thomas Dietrich; Walter C Willett Journal: J Bone Miner Res Date: 2009-05 Impact factor: 6.741
Authors: N Yoshimura; S Muraki; H Oka; T Iidaka; R Kodama; H Kawaguchi; K Nakamura; S Tanaka; T Akune Journal: Osteoporos Int Date: 2016-11-24 Impact factor: 4.507
Authors: Gillian Wheater; Mohsen Elshahaly; Kamran Naraghi; Stephen P Tuck; Harish K Datta; Jacob M van Laar Journal: PLoS One Date: 2018-08-06 Impact factor: 3.240